VolitionRx Schedules First Quarter 2015 Earnings Conference Call and Business Update for Tuesday, May 12, 2015 at 8:30 a.m. ET
VolitionRx Initiates Study with Hvidovre Hospital, Denmark, Specifically to Target NuQ(R) Biomarker Panel for Colorectal Polyps
VolitionRx Adds Three New Laboratory Automation Systems to Expedite Sample Analysis for its Large Ongoing Clinical Trials
VolitionRx Initiates Second Prostate Cancer Pilot Study Assessing Nucleosomics(R) Technology
VolitionRx Acquires Direct Ownership of Nucleosomics® Technology Patent
VolitionRx Limited Announces Exercise of Over-Allotment Option in Previously Announced Public Offering
VolitionRx Limited Announces Closing of Public Offering of Common Stock
VolitionRx Limited Prices Public Offering of Common Stock
VolitionRx Begins First Ovarian Cancer Detection Study
Initial Study Demonstrates that VolitionRx NuQ® Blood Test Has 84% Accuracy in Detecting Early Stage Treatable Pancreatic Cancers
